Tag: Xifaxan

According to the National Institutes of Health, rifaximin is a non-systemic oral antibiotic used to treat conditions like irritable bowel syndrome with diarrhea and traveler's diarrhea. The key to understanding **is rifaximin an antibiotic** and how it functions lies in its unique, minimally-absorbed nature, which restricts its activity to the gut.

Over 99% of Xifaxan remains in the gastrointestinal tract, making it a unique antibiotic that acts locally to treat specific gut-related conditions. So, what is Xifaxan used for? It is primarily prescribed to manage irritable bowel syndrome with diarrhea (IBS-D), reduce the risk of recurring hepatic encephalopathy (HE), and treat traveler's diarrhea caused by *E. coli*.

In the United States, an estimated 10-15% of adults suffer from symptoms of Irritable Bowel Syndrome (IBS). For those with the diarrhea-predominant subtype (IBS-D), a key question is, **what is rifaximin?** This gut-selective antibiotic offers a targeted treatment approach.

Clinical studies show that **Xifaxanta** (rifaximin) provides long-lasting relief for symptoms of irritable bowel syndrome with diarrhea (IBS-D) in some patients. This unique, non-systemic antibiotic is also approved to prevent a recurrence of hepatic encephalopathy and to treat traveler's diarrhea caused by *E. coli*.

According to research presented in 2024, Irritable Bowel Syndrome (IBS) affects millions of people, yet treatment satisfaction can be low. For those seeking relief, the question of what is the new medication for IBS is a persistent one, driving ongoing development in pharmacology for this chronic condition.